Sign in or Register   Sign in or Register
  |  

Mouse Anti-CD19 Recombinant Antibody (CB19) (CBMAB-C0522-CQ)

This product is a mouse antibody that recognizes CD19. The antibody CB19 can be used for immunoassay techniques such as: WB, FC, IHC, IF.
See all CD19 antibodies
Published Data

Summary

Host Animal
Mouse
Specificity
Human
Clone
CB19
Antibody Isotype
IgG1
Application
WB, FC, IHC, IF

Basic Information

Immunogen
Intact normal human B cell cells were used as immunogen to generate the CB19 clone
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
CD19 Molecule
Introduction
CD19 (CD19 Molecule) is a Protein Coding gene. Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency. Among its related pathways are RET signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. Gene Ontology (GO) annotations related to this gene include signal transducer activity, downstream of receptor.
Entrez Gene ID
UniProt ID
Alternative Names
CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; B-Lymphocyte Antigen CD19; CVID3; B4;
Function
Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed:2463100, PubMed:1373518, PubMed:16672701).
Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca2+ stores (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701).
Is not required for early steps during B cell differentiation in the blood marrow (PubMed:9317126).
Required for normal differentiation of B-1 cells (By similarity).
Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:2463100, PubMed:1373518).
Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701).
Biological Process
Antigen receptor-mediated signaling pathway Source: UniProtKB
B-1 B cell differentiation Source: Ensembl
B cell proliferation involved in immune response Source: UniProtKB
B cell receptor signaling pathway Source: UniProtKB
Immunoglobulin mediated immune response Source: UniProtKB
Positive regulation of phosphatidylinositol 3-kinase activity Source: UniProtKB
Positive regulation of protein kinase B signaling Source: Reactome
Positive regulation of release of sequestered calcium ion into cytosol Source: UniProtKB
Regulation of B cell activation Source: UniProtKB
Regulation of B cell receptor signaling pathway Source: UniProtKB
Regulation of complement activation Source: Reactome
Regulation of immune response Source: Reactome
Cellular Location
Cell membrane; Membrane raft
Involvement in disease
Immunodeficiency, common variable, 3 (CVID3): A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.
Topology
Extracellular: 20-291
Helical: 292-313
Cytoplasmic: 314-556
PTM
Phosphorylated on tyrosine following B-cell activation (PubMed:7684160, PubMed:7687539, PubMed:10706702, PubMed:12387743). Phosphorylated on tyrosine residues by LYN (PubMed:7687428). Tyrosine residues are phosphorylated sequentially after activation of the B cell receptor. Phosphorylation of Tyr-531 is extremely rapid, followed by phosphorylation at Tyr-409. In contrast, phosphorylation of Tyr-500 appears more slowly and is more transient, returning rapidly to basal levels (By similarity).

Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., ... & Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 27(8), 1419-1431.

Nerreter, T., Letschert, S., Götz, R., Doose, S., Danhof, S., Einsele, H., ... & Hudecek, M. (2019). Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nature communications, 10(1), 1-11.

Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., ... & Chen, S. Y. (2019). A safe and potent anti-CD19 CAR T cell therapy. Nature medicine, 25(6), 947-953.

Hatterer, E., Barba, L., Noraz, N., Daubeuf, B., Aubry-Lachainaye, J. P., von der Weid, B., ... & Buatois, V. (2019, February). Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation. In MAbs (Vol. 11, No. 2, pp. 322-334). Taylor & Francis.

Salter, A. I., Pont, M. J., & Riddell, S. R. (2018). Chimeric antigen receptor–modified T cells: CD19 and the road beyond. Blood, The Journal of the American Society of Hematology, 131(24), 2621-2629.

Bagashev, A., Sotillo, E., Tang, C. H. A., Black, K. L., Perazzelli, J., Seeholzer, S. H., ... & Thomas-Tikhonenko, A. (2018). CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Molecular and cellular biology, 38(21), e00383-18.

Turtle, C. J., Hay, K. A., Hanafi, L. A., Li, D., Cherian, S., Chen, X., ... & Maloney, D. G. (2017). Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor–modified T cells after failure of ibrutinib. Journal of Clinical Oncology, 35(26), 3010.

Alabanza, L., Pegues, M., Geldres, C., Shi, V., Wiltzius, J. J., Sievers, S. A., ... & Kochenderfer, J. N. (2017). Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Molecular Therapy, 25(11), 2452-2465.

Li, X., Ding, Y., Zi, M., Sun, L., Zhang, W., Chen, S., & Xu, Y. (2017). CD19, from bench to bedside. Immunology letters, 183, 86-95.

Liu, L., Lam, C. Y. K., Long, V., Widjaja, L., Yang, Y., Li, H., ... & Bonvini, E. (2017). MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies. Clinical Cancer Research, 23(6), 1506-1518.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-CD19 Recombinant Antibody (CB19)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare